# Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up

> **NCT06178770** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 414 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06178770
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-01
- **Primary completion:** 2022-12-12
- **Final completion:** 2022-12-12
- **Target enrollment:** 414 (ACTUAL)
- **Last updated:** 2023-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06178770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06178770, "Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06178770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*